Differences in the adsorption behaviour of poly(ethylene oxide) copolymers onto model polystyrene nanoparticles assessed by isothermal titration microcalorimetry correspond to the biological differences.

Transit of pharmaceutical dosage forms through the small intestine. Gut (1986) 2.35

PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release (1999) 2.08

Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87

Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res (1994) 1.61

Evaluation of impotence in older men. West J Med (1985) 1.54

The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res (1993) 1.53

Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun (1991) 1.50

Heavy metals in some Asian medicines and cosmetics. Public Health (1979) 1.42

Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst (1987) 1.42

Physicochemical properties of parenteral fat emulsions containing 20% triglyceride; Intralipid and Ivelip. J Clin Pharm Ther (1993) 1.40

Automated conductimetric titrimeter: use in studying ionic solute-solute interactions. J Pharm Sci (1975) 1.39

Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res (1994) 1.37

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35

Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30

Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res (1994) 1.30

Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci (1997) 1.28

Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 1.24

Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst (1994) 1.21

Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res (1991) 1.20

Chitosan microspheres prepared by spray drying. Int J Pharm (1999) 1.20

Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release (2001) 1.20

Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19

Microparticles as potentially orally active immunological adjuvants. Vaccine (1989) 1.19

The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett (1992) 1.17

Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab (1990) 1.16

Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond) (2011) 1.14

Compliance in medication by Asian immigrants. Nurs Times (1979) 1.13

Lead poisoning and traditional practices: the consequences for world health. A study in Kuwait. Public Health (1981) 1.13

Transport of nanoparticles across the rat nasal mucosa. J Drug Target (2001) 1.11

Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol (1991) 1.09

Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res (1997) 1.08

Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine (1995) 1.08

Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res (2002) 1.08

Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target (2001) 1.07

Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target (1993) 1.07

Lipid emulsions as drug delivery systems. Ann N Y Acad Sci (1987) 1.07

Epi-fluorescence microscopy and image analysis used to measure diffusion coefficients in gel systems. J Pharm Pharmacol (1992) 1.06

Controlled release microparticles for vaccine development. Vaccine (1991) 1.06

Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm (2000) 1.06

Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms. Int J Pharm (2004) 1.05

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine (2000) 1.04

The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev (2001) 1.04

An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta (1993) 1.04

Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmacol (1984) 1.03

Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm Res (1994) 1.02

Diamorphine infusion in the preterm neonate. Arch Dis Child (1991) 1.02

Targeting of drugs and vaccines to the gut. Pharmacol Ther (1995) 1.02

Techniques for the measurement of the rheological properties of sputum. Bull Physiopathol Respir (Nancy) (1973) 1.02

The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett (1984) 1.00

Intranasal delivery of morphine. J Pharmacol Exp Ther (2002) 0.99

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine (1995) 0.98

Structure and mucoadhesion of mussel glue protein in dilute solution. Biochemistry (1998) 0.98

Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res (1997) 0.97

The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release (1998) 0.97

Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul (1999) 0.97

Scientific principles in design of drug dosage formulations. Br Med J (1972) 0.96

Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem (1996) 0.96

Sugar cross-linked gelatin for controlled release: microspheres and disks. Biomaterials (1998) 0.96

Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm (2001) 0.95

Physical properties and stability of two emulsion formulations of propofol. Int J Pharm (2001) 0.95

Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J Control Release (2009) 0.95

The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol (1984) 0.93

In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res (1992) 0.93

Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol (1988) 0.93

Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Dig Dis Sci (1993) 0.92

The rheological properties of sputum. Biorheology (1969) 0.92

The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine (1999) 0.92

Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett (1994) 0.92

Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release (1999) 0.92

Preparation of surface-modified albumin nanospheres. Biomaterials (1997) 0.91

Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. FEMS Microbiol Lett (1993) 0.91

Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br J Clin Pharmacol (1990) 0.91

Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc (1988) 0.91

Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release (2001) 0.91

The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci (2001) 0.90